Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-6.72%
+35.16%
+1.40%
+4.07%
+0.45%
TEVA
Teva Pharma
$20.01
Login to see Teva Pharma (TEVA) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Upgraded on attractively valued
Trading below its fair value
Investors confidence is positive
Chart
$19.68 (+1.68%)
$16.42 (+21.86%)
$16.74 (+19.53%)
$17.95 (+11.48%)
TEVA has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
TEVA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Investors confidence is positive
Future
Future
Earnings are forecast to grow
Trading below its fair value
TEVA Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
TEVA Street view is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayTEVA Earnings
The TTM reflects 12-month period, providing review of TEVA financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
SNY
50.83
+1.48%
PFE
27.37
+1.05%
NVS
132.43
+1.11%
MRK
89.19
-0.42%
AZN
85.29
+1.94%
What is TEVA current stock price?
What are TEVA stock strengths?
What risks are associated with TEVA stock?
When is TEVA next earnings report?
What is TEVA market cap and volume?
What is TEVA's current Stock IQ?
Should I buy TEVA stock right now?
Is TEVA a Strong Buy right now?
What does a 'Strong Buy' rating mean for TEVA?
What does a 'Strong Sell' rating mean for TEVA?
What factors influence TEVA's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-6.72%
+35.16%
+1.40%
+4.07%
+0.45%
TEVA
Teva Pharma
Current Price
$20.01
Stock Insights
Strengths
Earnings are forecast to grow
Upgraded on attractively valued
Trading below its fair value
Investors confidence is positive
Linked to TEVA
SNY
50.83
+1.48%
PFE
27.37
+1.05%
NVS
132.43
+1.11%
MRK
89.19
-0.42%
AZN
85.29
+1.94%
Login to unlock Teva Pharma (TEVA) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$19.68 (+1.68%)
$16.42 (+21.86%)
$16.74 (+19.53%)
$17.95 (+11.48%)
TEVA Analysts Opinion
TEVA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Investors confidence is positive
Future
Future
Earnings are forecast to grow
Trading below its fair value
TEVA Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
TEVA Street view is bullish and have positive views on the near-term outlook
TEVA has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
Login to displayTEVA Earnings
The TTM data reflects the most recent 12-month period, providing overview of TEVA financial performance.
TEVA Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
TEVA Latest Analysis
Unpacking the Latest Options Trading Trends in Teva Pharmaceutical Indus. Investors with a lot of money to spend have taken a ish stance on TEVA).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals we don'.t know. But when something this big happens with TEVA it often means somebody knows something is about to happen.So how do we know what
Tue Sep 30, 2025
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term. Whether youre a value growth or momentum investor finding strong stocks becomes easier with the Zacks Style Scores a top feature of the Zacks Premium research service.
Tue Sep 30, 2025
Notable ETF Inflow Detected - IXUS PDD NU TEVA. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Core MSCI Total International Stock ETF (Symbol: IXUS) where we have detected an approximate $617.1 million dollar inflow -- thats a 1.3% in
Tue Sep 30, 2025
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript.
Wed Sep 24, 2025
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?. ALVOs partnership-driven model fuels surging biosimilar revenues while TEVA leans on scale but faces debt and competitive pressures.
Tue Sep 23, 2025
Bausch Teva face lawsuit for delay in generic version of Xifaxan.
Tue Sep 23, 2025
HEFA EFA TEVA MNDY: Large Outflows Detected at ETF. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Currency Hedged MSCI EAFE ETF (Symbol: HEFA) where we have detected an approximate $98.6 million dollar outflow -- thats a 1.5% decrease we
Fri Sep 19, 2025
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-749) on September 22 2025 After Presentations at the Psych Congress Annual meeting. TEL AVIV Israel Sept. 16 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting taking place from September 17 – 21 2025 in San Diego California.Teva will al
Tue Sep 16, 2025
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-749) on September 22 2025 After Presentations at the Psych Congress Annual meeting. TEL AVIV Israel Sept. 16 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting taking place from September 17 – 21 2025 in San Diego California.
Tue Sep 16, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
TEVA Stock trends
TEVA Stock performance
TEVA Stock analysis
TEVA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings